Meanwhile, RMST was used to evaluate the performance of the Kaplan-Meier curve, and we found had longer 3-year RMST in AML patients who are co-low expression of TXNIP, NLRP3 and CASP1 or TXNIP, NLRP3 and IL1B (3-year RMST: TXNIPlowNLRP3lowCASP1low vs. TXNIPhighNLRP3highCASP1high vs. TXNIPhigh or NLRP3high or CASP1high, 902 vs. 556 vs. 479 days; 3-year RMST: TXNIPlowNLRP3lowIL1Blow vs. TXNIPhighNLRP3highIL1Bhigh vs. TXNIPhigh or NLRP3high or IL1Bhigh, 946 vs. 600 vs. 490 days, Figure 2B and 2C). The gene discussed is IL1B; the disease is acute myeloid leukemia.